CBAR is proud to share the #CROI2024 abstract e-book and resources page, with over 20 posters featuring the work across #ACTG, #IMPAACT, and #PHACS networks. Congratulations to all the biostatisticians, epidemiologists and other staff on their contributions to research on HIV, COVID-19, TB, and other infectious diseases!
Center for Biostatistics in AIDS Research (CBAR)
Research Services
Boston, Massachusetts 597 followers
Follow CBAR for research updates, interviews with CBAR members, and new job openings.
About us
The Center for Biostatistics in AIDS Research (CBAR) is located within the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. CBAR's mission is to foster statistical science in clinical trials and other research studies in infectious diseases particularly HIV. CBAR pursues this mission by promoting innovative strategies for the design, data monitoring, analyses, and reporting of research studies, and by providing education and training relevant to statistical aspects of infectious disease research. As one of the largest staff Centers at the School, CBAR is comprised of >100 doctoral- and master’s-level biostatisticians, epidemiologists, and associated professional staff. These team members are at the forefront of statistical research related to the development of methods for the design and analysis of HIV clinical trials and observational studies, in the areas of HIV and infectious diseases. Our current research focuses on methods for patient-focused outcome measures that integrate efficacy and safety outcomes, for competing risks data, for personalizing treatment, and for comparison of technologies (e.g., point of care versus gold standard technologies). We also have a particular focus on the development and application of sophisticated epidemiological models for evaluating treatment benefits accounting for confounding by indication, such as the use of marginal structural models, mediation analysis, and other causal inference approaches. Our current training activities focus on programs for supporting the development of biostatistical expertise at institutions in Africa, South America, and South-East Asia. To learn more about the research projects please visit our page on the Harvard T. H. Chan School of Public Health website at: https://www.hsph.harvard.edu/cbar/
- Website
-
https://www.hsph.harvard.edu/cbar/
External link for Center for Biostatistics in AIDS Research (CBAR)
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Educational
- Founded
- 1995
- Specialties
- HIV and AIDS Research, Biostatistics, SAS Programming, Public Health, Clinical Trials, and Infectious Diseases
Locations
-
Primary
Get directions
651 Huntington Ave.
Boston, Massachusetts 02115, US
Employees at Center for Biostatistics in AIDS Research (CBAR)
-
Stephen Volante, CT
Spanish-French > English translation, proofreading/editing, US localization - Using experience, skill, and versatility to help clients
-
Heather Ribaudo
Director of Biostatistics and Programming, Center for Biostatistics In AIDS Research
-
Carlee Moser
Senior Research Scientist at Center for Biostatistics in AIDS Research
-
Jessica Lee
Epidemiologist at Center for Biostatistics in AIDS Research (CBAR)
Updates
-
The #ACTG A5359 study showed that long-acting ART with cabotegravir and rilpivirine is more effective than oral ART for people who have had challenges with adherence. Congratulations to all CBAR statisticians and epidemiologists for all their work on this study! Read more here:
Statement: Long-Acting HIV Treatment Demonstrates Efficacy in People with Challenges Taking Daily Medicine as Prescribed
niaid.nih.gov
-
On this 35th anniversary of #WorldAIDSDay, the Center for Biostatistics in AIDS Research extends gratitude to our participants, site staff, data managers, clinical investigators, epidemiologists, statisticians, administrative and creative staff, leadership, and others involved with our networks for all their work and dedication towards improving the health of people living with HIV/AIDS. We would also like to share #NICHD's spotlight article reflecting on recent progress in HIV research, in which various #PHACS studies were referenced. We hope to continue fulfilling our mission and collaborating with our communities to contribute to advancing HIV/AIDS research. https://lnkd.in/eFdjTdDz
Spotlight: Reflecting on Recent Progress in HIV Research
nichd.nih.gov
-
The Center for Biostatistics in AIDS Research currently has positions open for the Research Associate/Research Scientist position for both #ACTG and #IMPAACT networks. If you are interested in joining over 100 statisticians, epidemiologists, and research staff to collaborate on the design, monitoring, analysis, and reporting of Phase I through Phase IV clinical trials, diagnostic studies, and observational studies, consider applying! More details on the positions can be found in the links below: https://lnkd.in/epJNpmKv https://lnkd.in/e3QR5WM2
Research Associate/Research Scientist (ACTG)
academicpositions.harvard.edu
-
The ACTIV-2 / #ACTG team developed a series of manuscripts addressing secondary questions and design topics related to #COVID19 RCT designs. The ACTIV-2 Supplement is now published in the Journal of Infectious Diseases! Read the individual articles here: https://lnkd.in/eZUQiKsC
The Journal of Infectious Diseases
academic.oup.com
-
A study conducted by #PHACS has shown that young adults living with perinatally-acquired HIV (YAPHIV) with average or high levels of social support were more likely to maintain viral suppression compared to those with low social support. The study included 444 YAPHIV enrolled in the AMP Up study. Social support was measured with the NIH Toolbox and covered emotional, instrumental, and friendship social support. Read full article here: https://lnkd.in/eNyUcYK9
Science Update: Social support promotes HIV suppression among young adults, NIH-funded study suggests
nichd.nih.gov
-
Exciting news that data from #IMPAACT studies have resulted in recent FDA approvals of antiviral drugs: 1) Once-daily child friendly dispersible tablet containing 3 antiretrovirals for infants and children (IMPAACT 2019) 2) Supplemental new drug application from #GileadSciences that provided pharmacokinetic and safety data from pregnant individuals with #COVID19 treated with remdesivir (IMPAACT 2032) Read more here: https://lnkd.in/eiihJSMx https://lnkd.in/eiihJSMx
Data from IMPAACT 2019 Contribute to FDA Approval of a Once-Daily Dispersible HIV Drug for Young Children | IMPAACT
impaactnetwork.org
-
Results from the REPRIEVE Trial, now published in NEJM, have shown that the risk of a major adverse cardiovascular event was lowered in participants living with HIV who received pitavastatin compared to who received placebo. A huge thank you to the team at CBAR whose hard work made it possible to get these data published! Links to additional press releases can be found here: https://lnkd.in/e-4Y2rxh https://lnkd.in/ezb4J5cA
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection | NEJM
nejm.org